 |
|||||||||
|
 |
 As a result of an extensive global manufacturing network review, Pfizer Inc. is consolidating its manufacturing operations. As part of this consolidation exercise PricewaterhouseCoopers LLP is currently working with Pfizer to explore strategic options of its UK-based, Morpeth manufacturing facility, including a possible sale. This summary is intended to provide an overview of the Facility. Further information regarding the opportunity will be made available to your organisation if you express a strong interest to explore it further.
The Facility sells the majority of its products to other Pfizer group companies. As part of any sales offering, the Facility will be sold with medium and long term transitional supply contracts, with Pfizer, for certain of the Facility's key products. These transitional supply contracts would allow an acquiror:
In parallel with fulfilling the transitional supply contracts, the Facility has the flexibility, management experience, and manufacturing capacity available to allow it to develop and manufacture a wide range of new products on site. Details of the Facility's historic reported indicative standard costs for 2004, total production volumes in 2004, spare capacity in 2004 and a selection of the key products currently manufactured on the site include:
The Facility has been in operation for over 30 years with previous owners including Searle, Monsanto and Pharmacia. It is situated on a 50 acre freehold site approximately 15 miles north of Newcastle upon Tyne, a major city in the North east of England. Approximately 20 acres of the site remain to be developed. There are currently circa 500 experienced staff led by a highly motivated and experienced senior management team with a successful record of new product introduction, process improvement, continuous cost reduction and regulatory compliance. Morpeth's staff has vast experience meeting customer requirement on a global basis. |
|||||||
 |
|||||||||
The Facility, based at Morpeth in the North East of England, is a fully integrated manufacturing site encompassing API, pharmaceutical and packaging operations. There are also specialised containment and finishing facilities.
